Interferon beta-1a long-term therapy related to pulmonary arterial hypertension in multiple sclerosis patients

Anthony Fok, Trevor Williams, Catriona A. McLean, Ernest Butler

Research output: Contribution to journalArticleOtherpeer-review

12 Citations (Scopus)


We report two patients with relapsing remitting multiple sclerosis (RRMS) on interferon (IFN) beta-1a treatment for more than 7 years who developed pulmonary arterial hypertension (PAH). Patient 1 developed severe PAH requiring lung transplantation. Histology showed typical proliferative lesions including plexiform lesions consistent with PAH. Patient 2 ceased IFN beta-1a, and their symptoms stabilised. Both cases highlight IFN beta-1a treatment as a potential risk factor for PAH. PAH needs to be considered as a diagnosis in patients on long-term IFN beta-1a treatment who develop new-onset respiratory symptoms.

Original languageEnglish
Pages (from-to)1495-1498
Number of pages4
JournalMultiple Sclerosis Journal
Issue number11
Publication statusPublished - 1 Oct 2016


  • Beta-interferon
  • interferon
  • multiple sclerosis
  • pulmonary arterial hypertension

Cite this